loncastuximab tesirine

Loncastuximab tesirine (Zynlonta) is an antibody-drug conjugate (ADC) developed by ADC Therapeutics S.A. for the treatment of relapsed or refractory B-cell lymphomas. It consists of a humanized monoclonal antibody targeting the B-lymphocyte antigen CD19, which is highly expressed on the surface of B-cell malignancies. The antibody is conjugated via a protease-cleavable valine-alanine linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxic payload, SG3199. Upon binding to CD19, the ADC is internalized, and the PBD payload is released through enzymatic cleavage. The payload then binds covalently in the DNA minor groove, forming potent DNA interstrand cross-links that inhibit DNA replication and induce cell death. It received accelerated FDA approval in April 2021 for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBCL) after two or more lines of systemic therapy.

Brand names

Zynlonta

Other names

Loncastuximab tesirine-lpylLonca